CareDx
CareDx is a publicly traded precision medicine company (NASDAQ:CDNA) that develops molecular diagnostics, AI-powered analytics, digital health tools, and patient services for the transplant care continuum, serving U.S. transplant centers, healthcare providers, and patients, with a pending expansion into oncology diagnostics.
- Company typePublic
- Founded2000
- HeadquartersBrisbane, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What CareDx does
CareDx, Inc. (NASDAQ:CDNA) is a publicly traded precision medicine company founded in 1998 and headquartered in Brisbane, California, that develops and commercializes molecular diagnostics, IVD products, digital health tools, and clinical services for the transplant care continuum. Its core diagnostic franchise is built on non-invasive molecular testing: AlloSure and AlloSure Plus use donor-derived cell-free DNA (dd-cfDNA) to detect allograft injury in kidney transplant recipients, with KOAR registry data showing 3.7x and 6.4x higher adjusted hazards of graft loss at intermediate and high elevation states; AlloMap and HeartCare combine gene expression profiling with dd-cfDNA for heart transplant surveillance, validated in the 1,934-patient SHORE registry; and the pipeline includes AlloHeme, an AI-powered NGS blood test for AML/MDS relapse detection targeting a 2027 commercial launch. Pre-transplant HLA typing products include AlloSeq Tx, QTYPE, and the recently launched AlloSeq Nano nanopore platform; tissue-based classifiers include HistoMap Kidney and HistoMap Heart. AlloSure Plus achieved an AUROC of 0.79 for rejection discrimination.
CareDx's technology stack is anchored by three proprietary multi-organ transplant registries (KOAR, SHORE, ALAMO) and the VANTx AI-powered cloud-native clinical data and analytics platform, which runs Meta's Llama 3 foundation model in a Databricks environment against the company's longitudinal datasets for cohort analysis, clinical research, and predictive modeling. The company also operates the AlloCare mobile application (medication reminders, lab results, vital sign tracking, with HIPAA-compliant PHI sharing), the CareDx Care Team (clinical and operational patient support, mobile phlebotomy scheduling, billing/financial assistance), and the CareDx Transplant Pharmacy (filling 150,000+ prescriptions annually), with workflow software products used by approximately 70% of U.S. transplant centers and cumulative molecular test volume exceeding 1 million.
The business model is reimbursement-driven and multi-stream: testing services revenue (Q1 2026: $91.4 million, +48% YoY on ~54,900 tests) is usage-based, anchored by Medicare ADLT designation at $1,800 per test for select products; patient and digital solutions revenue (Q1 2026: $16 million, +33% YoY) reflects recurring digital health and pharmacy revenue; and products revenue from IVD kits is being divested to EuroBio Scientific for $170 million in cash (expected to close Q3 2026), with CareDx retaining exclusive perpetual North American distribution rights. The pending $260 million acquisition of Naveris will add the NavDx liquid biopsy for HPV-driven cancer MRD surveillance into a new oncology vertical, expanding the total addressable market to $12.5 billion. Customers are primarily U.S. transplant centers and healthcare providers, reached through an enterprise field sales motion, heavy conference presence (ATC, ISHLT, ASN, Tandem, EFI, ASHI), and direct-to-patient digital engagement.
CareDx firmographics
Firmographics- Name
- CareDx
- Legal name
- CareDx, Inc.
- Website
- https://caredx.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- CareDx is a publicly traded precision medicine company (NASDAQ:CDNA) that develops molecular diagnostics, AI-powered analytics, digital health tools, and patient services for the transplant care continuum, serving U.S. transplant centers, healthcare providers, and patients, with a pending expansion into oncology diagnostics.
- Ownership category
- akta.pro rank
CareDx industry classification
Industry- Product category
- Transplant Diagnostics
- NAICS
- Home Health Care Services (62161), All Other Outpatient Care Centers (621498)
- SIC
- Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Post-Acute & Transitional Care Virtual Platforms (SNF/home health coordination) (HLALABAG)
Keywords
Where CareDx is headquartered
LocationHeadquarters
- HQ city
- Brisbane
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
CareDx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Testing Services Revenue: Recurring revenue from non-invasive molecular diagnostic tests (AlloSure, AlloMap, HeartCare) performed for transplant recipients. Q1 2026 testing services revenue was $91.4 million, up 48% year-over-year, with testing service volume reaching approximately 54,900 tests in Q1 2026 and full year 2025 volume of approximately 200,000 tests. Reimbursement-driven with Medicare ADLT designation at $1,800 per test for some products.
- Patient and Digital Solutions Revenue: Recurring revenue from digital health platforms, patient management apps, mobile phlebotomy services, and the CareDx Care Team. Q1 2026 revenue was $16 million, up 33% year-over-year, including pharmacy services that fill 150,000+ prescriptions annually.
- Products Revenue (Lab Products / IVD): One-time and recurring revenue from sales of IVD kits including AlloSeq Tx, QTYPE HLA typing products, and laboratory reagents. Approximately 200,000 HLA typing kits sold annually. This segment is being divested to EuroBio Scientific for $170 million in cash, expected to close by end of Q3 2026, with EuroBio granting CareDx exclusive perpetual distribution rights in North America.
- Oncology Diagnostics Revenue (post-Naveris): Future revenue stream from Naveris acquisition (up to $260 million deal) including the NavDx liquid biopsy blood test for HPV-driven cancers. Naveris reported $34 million in unaudited 2025 revenue with 65% gross margins, projected 30-40% annual growth over three years. Recognized by Medicare and addressing a $4.5 billion TAM.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Quote-based pricing for healthcare providers and transplant centers |
Go-to-market motion3 records
CareDx product offering
Product offeringCore offering
CareDx is a transplant-focused precision medicine company that develops and delivers non-invasive molecular diagnostic tests (dd-cfDNA, gene expression, HLA typing), transplant lab products (IVD kits), digital health solutions (AlloCare mobile app, CareDx Care Team, CareDx Pharmacy), and workflow software used by transplant centers. The integrated platform supports patients and clinicians across the entire transplant journey, from pre-transplant HLA typing through post-transplant rejection surveillance and graft health monitoring.
Product overview
CareDx is a transplant-focused precision medicine company delivering an integrated platform-plus-modules architecture for the entire transplant journey. Its molecular diagnostics core includes AlloSure and AlloSure Plus (dd-cfDNA monitoring for kidney), AlloMap (gene expression testing for heart), HeartCare (combined heart transplant surveillance), AlloSure Heart and AlloSure Lung, and AlloView (kidney rejection). Pre-transplant HLA typing solutions include AlloSeq Tx, AlloSeq Tx11, AlloSeq Nano (long-read), and QTYPE. Tissue biopsy-based products include HistoMap Kidney and HistoMap Heart. Patient and digital solutions span the AlloCare mobile app, the CareDx Care Team clinical support service, the CareDx Transplant Pharmacy (filling ~150K prescriptions annually), and RemoTraC. Workflow software products (used by ~70% of transplant centers) support transplant program management. CareDx's newer precision medicine platform includes VANTx (an AI-powered clinical data and analytics platform), AlloHeme (NGS surveillance for AML/MDS), the ImmuneScape multiomics research program, and the upcoming NavDx liquid biopsy test (via the Naveris acquisition, pending close Q3 2026) for HPV-driven cancer MRD surveillance.
Differentiator
Problem solved
Functional benefit
Brands
- AlloCare: Mobile patient app for transplant patients providing medication reminders, adherence monitoring, and access to lab results and educational content.
- AlloSure
- AlloMap
- AlloSure Plus
- HeartCare
- AlloSeq Nano
- AlloSeq Tx
- QTYPE
- HistoMap
- ImmuneScape
- AlloHeme
- VANTx
- NavDx
- RemoTraC
- AlloView
Products and services
- AlloSure Donor-derived cell-free DNA (dd-cfDNA) test used for non-invasive monitoring of kidney, heart, and lung transplant injury, evolving from a surveillance biomarker toward a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes. Targeted at transplant nephrologists, cardiologists, and pulmonologists.
- AlloSure Plus Next-generation version of AlloSure that achieved an AUROC of 0.79 for discriminating rejection in studies presented at the American Transplant Congress 2026.
- AlloMap Gene expression test used for non-invasive heart transplant rejection surveillance, often deployed as part of the HeartCare combination offering.
- HeartCare Combination non-invasive molecular testing product for heart transplant patients (combining AlloMap and AlloSure Heart), demonstrated in the SHORE registry (1,934 patients, 59 centers) to predict graft dysfunction and cardiovascular death independent of biopsy results.
- AlloSure Lung dd-cfDNA-based surveillance test for lung transplant recipients, with prognostic findings from the ALAMO lung transplant registry presented at ISHLT 2026.
- AlloView Molecular diagnostic test for assessing kidney transplant rejection and graft health, presented alongside HistoMap Kidney at ASN Kidney Week 2025.
- AlloSeq Tx / AlloSeq Tx11 HLA typing kit with AlloSeq Tx11 adding enhanced Class II coverage and non-HLA markers; IVDR certified at the 2025 ASHI Annual Meeting. Used in transplant and donor typing laboratories.
- AlloSeq Nano Nanopore-based HLA and ABO blood type genotyping solution providing high-resolution HLA typing in under three hours with a single-step workflow (~45 minutes hands-on time for 11 HLA loci plus ABO). Launched at EFI 2026.
- QTYPE HLA typing product that received IVDR certification alongside AlloSeq Tx at the 2025 ASHI Annual Meeting.
- AlloSeq cfDNA 2.0 Next-generation cfDNA-based transplant diagnostic kit launched by CareDx in 2026 as part of its Lab Products portfolio.
- HistoMap Kidney Tissue biopsy-based gene expression classifier for characterizing kidney transplant rejection, launched at ASN Kidney Week 2025.
- HistoMap Heart Spatial transcriptomics and molecular diagnostic for heart transplant rejection classification, highlighted at the American Transplant Congress 2026.
- AlloCare Mobile App Patient mobile app providing educational content, medication reminders, vital sign tracking, lab result delivery, and adherence support for transplant patients, caregivers, and healthcare providers. Supports third-party account login via Facebook.
- VANTx AI Platform AI-powered, cloud-native clinical data and analytics platform built on CareDx's longitudinal solid organ transplant datasets, using Meta's Llama 3 foundation model on a Databricks environment. Supports cohort analysis, clinical research, and real-world evidence development with predictive models for kidney, heart, lung, and liver transplant research.
- AlloHeme AI-powered NGS-based blood surveillance test for predicting relapse in AML and MDS patients following allogeneic hematopoietic cell transplantation. Demonstrated 85% sensitivity, 92% specificity, and median 41-day lead time over standard clinical detection in the ACROBAT study. Targeted for U.S. CLIA readiness in 2026, commercial launch in 2027, and Medicare coverage in 2028.
- CareDx Care Team Personalized care team service providing medical-led review of patient results, customized alerts, protocol adherence reviews, scheduling, mobile phlebotomy coordination, dedicated 1:1 patient care navigation, and adherence reminders for transplant patients.
- CareDx Transplant Pharmacy Specialty pharmacy operation that fills approximately 150,000 prescriptions annually for transplant patients.
- CareDx Workflow Products Operational software solutions for transplant program management, used by approximately 70% of transplant centers.
Companies that use CareDx
Customer profileSegments5 records
Ideal customer profiles4 records
CareDx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability10 records
Feature9 records
CareDx partnerships and signals
Strategic signalScale indicators19 records
Recent moves7 records
Expansion highlights6 records
CareDx competitors and assessment
Company assessmentDirect peers
- Natera: Natera is the most direct competitor to CareDx in transplant surveillance, offering its own Prospera dd-cfDNA test for kidney, heart, and lung transplant monitoring. The two companies are actively engaged in patent and false advertising litigation, underscoring their direct overlap in transplant molecular diagnostics.
Broad incumbents
- Veracyte: Veracyte is a specialty molecular diagnostics company with similar precision medicine positioning, and CareDx's new COO/CFO Keith Kennedy previously served as Veracyte's COO/CFO/Secretary. Comparable in business model as a public diagnostics platform with multi-test portfolios and Medicare reimbursement exposure.
- Exact Sciences: Exact Sciences is a larger public molecular diagnostics company specializing in non-invasive cancer screening and surveillance tests (Cologuard, Oncotype). Comparable to CareDx in scaling Medicare-reimbursed molecular diagnostics and pursuing AI-enabled biomarker expansion into oncology.
- Guardant Health: Guardant Health is a leading liquid biopsy and precision oncology company offering blood-based cancer screening and monitoring tests. Overlaps with CareDx post-Naveris in viral-mediated cancer MRD surveillance and shares the ADLT-designated, Medicare-reimbursed test business model.
- NeoGenomics: NeoGenomics provides oncology-focused clinical laboratory and molecular diagnostic services across solid tumors and hematologic malignancies. Comparable to CareDx as a public, multi-modality diagnostics company with a growing hospital and transplant-center channel and recurring test revenue.
- Bio-Techne: Bio-Techne is a global life sciences tools and diagnostics company offering reagents, assays, and spatial biology products (including RNAscope and the COMET platform acquired with Lunaphore) used in transplant and immunology research. Comparable to CareDx in providing tools underpinning transplant diagnostics innovation.
- Foundation Medicine: Foundation Medicine is a leading molecular genomics and precision oncology company offering comprehensive genomic profiling tests. Comparable to CareDx in applying NGS-based molecular profiling and AI analytics to inform clinical decision-making in oncology and specialty disease areas.
Regional players
- EuroBio Scientific: EuroBio Scientific is acquiring CareDx's Lab Products business for $170M and has become CareDx's exclusive perpetual distributor of post-transplant monitoring IVD tests in North America. Operates in adjacent transplant diagnostics and HLA typing markets primarily across Europe.
Emerging players
- 10x Genomics: 10x Genomics is the strategic partner for CareDx's ImmuneScape multiomics research program, providing Xenium spatial transcriptomics and Chromium Flex single-cell platforms. Both companies are advancing single-cell and spatial biology tools into clinical research applications, with overlapping transplant and immunology customer bases.
- Adaptive Biotechnologies: Adaptive Biotechnologies provides immune-based diagnostics using NGS for clonoSEQ MRD testing and immunoSEQ immune profiling. Highly comparable to AlloHeme in applying AI-powered NGS to MRD and minimal residual disease detection across hematologic malignancies and post-cell therapy surveillance.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
CareDx social profiles
Digital presenceCareDx compliance and trust
Trust signalCompliance12 records
CareDx financial estimates
Financial estimateRevenue estimate
Valuation estimate
CareDx leadership team
Management profileNumber of profiles
Profiles5 records
CareDx subsidiaries and ownership
Company hierarchySubsidiaries5 records
CareDx funding detail
Funding detailFunding overview
Funding rounds19 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CareDx M&A and investment
M&A and investmentM&A10 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CareDx
What does CareDx do?
CareDx is a transplant-focused precision medicine company that develops and delivers non-invasive molecular diagnostic tests (dd-cfDNA, gene expression, HLA typing), transplant lab products (IVD kits), digital health solutions (AlloCare mobile app, CareDx Care Team, CareDx Pharmacy), and workflow software used by transplant centers. The integrated platform supports patients and clinicians across the entire transplant journey, from pre-transplant HLA typing through post-transplant rejection surveillance and graft health monitoring.
Is CareDx a public or private company?
CareDx is a public company. It is classified as public and is currently operating.
When was CareDx founded?
CareDx was founded in 2000. It employs 501 to 1,000 people.
Where is CareDx based?
CareDx is headquartered in Brisbane, United States, in the North America region.
How does CareDx make money?
Four revenue lines are on record. Testing Services Revenue is the primary driver. The others are patient and Digital Solutions Revenue, products Revenue (Lab Products / IVD) and oncology Diagnostics Revenue (post-Naveris).
Who are CareDx's main competitors?
Natera is listed as a direct peer. Broad incumbents are Veracyte, Exact Sciences, Guardant Health, NeoGenomics, Bio-Techne and Foundation Medicine. EuroBio Scientific is listed as a regional player. Emerging players are 10x Genomics and Adaptive Biotechnologies.
Does CareDx have an API?
No public API is recorded for CareDx.
What industry is CareDx in?
CareDx's product category is Transplant Diagnostics. Its primary akta.pro industry code is HLALABAG, Post-Acute & Transitional Care Virtual Platforms (SNF/home health coordination). Its NAICS code is 62161 and its SIC code is 8071.